Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 in Relapsed/Refractory CD19+ AML
NCT03896854Phase 2Recruiting
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19 CAR-T cells in acute myeloid leukemia (AML), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoint: Adverse events at 12 months. Started Oct 2017; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03896854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896854.